Discover the

future

of biotech

Your best source for early-stage biotech signals

PERSONALIZED BIOTECH INTELLIGENCE

Stop reading biotech news that isn't relevant to you

Make a profile. Tell us your role, your therapeutic areas, and the companies you’re watching. We’ll deliver a personalized briefing with only the signals that matter to your work.

🔥HOT SIGNALS

April 15, 2026

20 Minutes to Burn a Pancreatic Tumor

Sonire Therapeutics closes $18M Series A for focused ultrasound ablation in pancreatic cancer.

April 14, 2026

Lilly Bought a Dual-Payload ADC Before It Hit the Clinic. Here’s Why.

Eli Lilly acquires CrossBridge Bio and its dual-payload ADC platform before any clinical data.

PERSONALIZED BIOTECH INTELLIGENCE

Stop reading biotech news that isn't relevant to you

Make a profile. Tell us your role, your therapeutic areas, and the companies you’re watching. We’ll deliver a personalized briefing with only the signals that matter to your work.

📰 RECENT ARTICLES

April 15, 2026

Mesoblast Puts a CAR on a Stem Cell

April 15, 2026

An EP300/CBP Inhibitor Designed to Clear Before It Hurts

April 15, 2026

RNA-Targeting Small Molecules Pass Their First Pharma Test

April 15, 2026

A Dual-Pathway Peptide for the Pain Chemo Leaves Behind

April 15, 2026

An Implantable Muscle Interface for Amputees Enters First-in-Human

PERSONALIZED INTELLIGENCE

Get your own bi-weekly briefing.
For free.

Tell us your role, your therapeutic areas, and the companies you’re watching. We’ll deliver a briefing with only the signals that matter to your work — ranked, contextualized, and written for you.

Powered by HOUSTON | FLYTE Bio Intelligence Platform

INTELLIGENCE REPORTS

Landscape Reports

Deep-dive intelligence reports mapping the companies shaping biotech’s next chapter.

Powered by HOUSTON | FLYTE Bio Intelligence Platform

AI In Biotech

How will AI change biotech in the next 3-5 years

View All

Novo Nordisk Called OpenAI. So Did Everyone Else.

AI In Biotech

Novo Nordisk partners with OpenAI as AI drug discovery deal flow surpasses $5B in five months.

One Bought a Podcast. The Other Bought a Lab.

AI In Biotech

Anthropic dropped $400M on a 9-person biotech AI startup. The same day, OpenAI bought a podcast. That tells you everything.

$787 Million Says AI Can Design Better Biologics Than You

AI In Biotech

An AI-native biologics company just raised $787M with Sanofi and a Pfizer/Hillhouse fund backing it — and they already have a Phase 2 asset.

Teaching a Gene Editor to Optimize Itself

AI In Biotech

Specific Biologics just got government funding to build a machine learning layer on top of its Dualase gene editing platform — targeting repeat expansion diseases like ALS.

EMERGING MODALITIES

Tracking the next therapeutic wave before it breaks

View All

Lilly Bought a Dual-Payload ADC Before It Hit the Clinic. Here’s Why.

Emerging Modalities

Eli Lilly acquires CrossBridge Bio and its dual-payload ADC platform before any clinical data.

An Auger-Emitting Radioconjugate for Triple-Negative Breast Cancer

Emerging Modalities

Cellectar Biosciences enrolls first patient in Phase 1b of CLR 125, an iodine-125 Auger emitter targeting refractory TNBC.

Deck Bio’s T Cell Engagers Target Multiple Intracellular Targets. That’s a Big Deal.

Emerging Modalities

Deck Bio launches a multi-target pMHC T cell engager platform that hits multiple intracellular cancer antigens with a single binder.

“Cue” The Music. $7.5M for Picking the Right Molecule.

Emerging Modalities

Cue Biopharma earns a $7.5M preclinical milestone from Boehringer Ingelheim for its CUE-501 autoimmune program.

COMPANY PROFILES

The companies shaping the future of biotech

View All

Deck Bio

April 9, 2026

Multi-target T cell engagers redirecting immunity against intracellular cancer antigens in solid tumors.

Ternary Therapeutics

April 6, 2026

AI-driven platform designing molecular glue therapeutics for undruggable targets in immunology and neuroinflammation.

Stipple Bio

April 6, 2026

Epitope-resolution platform discovering tumor-specific cell surface targets for precision ADCs and next-generation oncology therapeutics.

TRIANA Biomedicines

April 4, 2026

Rational molecular glue degrader platform targeting undruggable oncology targets, with lead ALK fusion degrader in Phase 1/2 for NSCLC.